搜索结果: 1-6 共查到“肿瘤学 status”相关记录6条 . 查询时间(0.206 秒)
Changing status of investigations for prostate cancer detection
Before the serum prostate specific antigen prostate cancer androgen treatment the prostate gland
2017/2/22
Before the introduction of serum prostate specific antigen for the early detection of prostate cancer, this condition was diagnosed at an advanced stage, with palliative androgen deprivation therapy t...
Nutritional status and fitness in neoadjuvant chemoradiation for oesophagogastric cancer
Nutritional status and fitness neoadjuvant chemoradiation oesophagogastric cancer
2015/4/2
Resectable oesophagogastric cancer typically requires neoadjuvant chemoradiation therapy followed by surgical resection of the primary tumour. Consideration for surgery is on the basis of the risk–ben...
Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
Pemetrexed Lung neoplasms Poor performance
2013/12/6
Background and objective Pemetrexed have been approved for the treatment of patients affected by advanced non-small cell lung cancner (NSCLC) in progression after first-line chemotherapy. We evaluated...
Correlation of HER2/neu Over Expression,p53 Protein Accumulation and Steroid Receptor Status with Tumor Characteristics: An Iranian Study of Breast Cancer Patients
Breast Cancer HER2/neu p53 Steroid Receptor Stage Iran
2009/12/7
Background: Molecular biomarkers are valuable in evaluation the course of malignancies. In this study, the relationship between HER2/neu, p53, steroid receptors and clinicopathological features o...
PATIENTS OUTCOME IN A RANDOMIZED TRIAL ACCORDING TO THE STATUS OF HLA ANTIGENS IN GASTRIC AND COLORECTAL CANCERS AND SECONDARY MALIGNANCIES
putative HLA antigen resection of the tumors response to therapy secondary malignancies
2009/7/15
Purpose: Previous studies showed that HLA-B40 and -B51 antigens were associated with the response to immunotherapy using protein-bound polysaccharide (PSK) and chemotherapy, respectively, in gastric c...
Current status of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) targeting cancer therapy
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) TRAIL receptor 1 (TRAIL-R1), TRAIL receptor 2 (TRAIL-R2) apoptosis KM mouseTM monoclonal antibody targeting therapeutics
2009/7/15
Monoclonal antibodies have already established a secure position as a very promising strategy for anti-tumor therapeutics. High specificity and high affinity are attractive characteristics of antibodi...